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6.1% (n=10) were genotype 3b. 3.0% (n=5) were genotype 1a. n=
01 had genotype 1b. 4.2% (n= 7) had mixed genotype (3a, 3b/1a,
1b, 3a, 3b).
Conclusion: Majority (85.9%) of chronic hepatitis C patients were
genotype 3a which is associated with favorable outcome after 24
weeks of conventional interferon and ribavirin therapy and only
3.0% had genotype 1a in this cohort.
PP-130 Virological response in relation to biochemical
changes in chronic hepatitis C patients in a
tertiary care hospital in Pakistan
Adnan Raja*, Muhammad Umar, Hammamatul Bushra.
Gastroenterology and Hepatology division, Department of
Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Background: Alanine aminotransferase is an enzyme produced in
hepatocytes and its raised levels in serum indicate hepatocyte
damage. Furthermore, the number of patients with sustained
viral response (SVR) and with sustained ALT normalization in
non-SVR patients was also signiﬁcantly higher in the combination
therapy versus monotherapy group.
Objectives: To study the effect of Initial ALT levels on predicting
sustained virological response in HCV infected patients getting
conventional Interferon alpha 2b and Ribavirin combination ther-
apy in the Gastroenterology and Hepatology division of Holy
Family Hospital under the National program for prevention and
control of hepatitis in Pakistan.
Methodology: Retrospective observational study on the records
of patients diagnosed as HCV positive coming for conventional
Interferon and Ribavirin therapy to the Gastroenterology and
Hepatology division of Holy Family Hospital under the National
program for prevention and control of hepatitis in Pakistan. It is
to be noted that pathology lab at Holy Family Hospital takes a
value less than or equal to 45 U/L as normal.
Results (n=89): Group I: ALT ≤ 45
– n=25; SVR achieved 80.0%, n=20; Relapser 20.0%, n=05
Group II: ALT 45-90
– n=33; SVR achieved 81.8%, n=27; Relapser 18.8%, n=06
Group III: ALT > 90
– n=31; SVR achieved 64.5%, n=20; Relapser 35.5%, n=11
Conclusion: It was concluded that there is signiﬁcant PCR neg-
ativity at 24 weeks in patients with ALT levels upto 90 U/L as
compared to the patients with ALT levels more than 90 U/L.
PP-131 Biochemical Response with interferon alpha 2b
and ribavirin combination therapy in chronic
hepatitis C patients
Adnan Raja*, Muhammad Umar, Hammamatul Bushra.
Gastroenterology and Hepatology division, Department of
Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Background/Aim: Alanine aminotransferase is an enzyme pro-
duced in hepatocytes and its raised levels in serum indicate
hepatocyte damage. Conventional Interferon being an immune
modulator and Ribavirin being a nucleoside analogue antiviral
drug is believed to suppress hepatocyte damage and inﬂamma-
tion and so decrease the levels of ALT in serum of patients with
high ALT levels undergoing combination therapy. The aim is to
study the changes in ALT levels in HCV infected patients get-
ting conventional Interferon alpha 2b and Ribavirin combination
therapy
Methodology: Retrospective observational study on the records
of patients diagnosed as HCV positive coming for conventional
Interferon and Ribavirin therapy to the Gastroenterology and
Hepatology division of Holy Family Hospital under the National
program for prevention and control of hepatitis in Pakistan. It is
to be noted that pathology lab at Holy Family Hospital takes a
value less than or equal to 45 U/L as normal.
Results (n=663): At the start of combination therapy the mean
ALT levels were 80.20 with std. deviation of 66.176 and after
06 months of therapy the mean ALT levels were 41.47 with std.
deviation of 42.194. Furthermore, 461 patients had ALT levels
more than 45 before starting combination therapy and out of
these 461 patients 69.6%, n= 321 had normalization of ALT levels
(<45 IU/L).
Conclusion: It was concluded that use of Conventional Interferon
alpha 2b and Ribavirin combination therapy in patients with
chronic Hepatitis C, ALT levels show trend towards Normaliza-
tion.
PP-132 Thrombocytopenia in chronic hepatitis C patients
treated with conventional interferon and
ribavirin in a tertiary care hospital of Rawalpindi,
Pakistan
Adnan Raja*, Muhammad Umar, Hammamatul Bushra.
Gastroenterology and Hepatology division, Department of
Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Background: Thrombocytopenia is one of the major adverse
effects of IFN-α and ribavirin often leading to dose reduction or
treatment discontinuation. Recent data demonstrated that 4-6%
of patients underwent dose modiﬁcation secondary to thrombo-
cytopenia. Reduction of the dose is recommended at 50,000 cell
count/cmm and discontinuation, if the platelet count drops be-
low 30,000 cell/cmm. It is now a known fact that dose reduction
or interruption of therapy leads to lesser SVR.
Methods: This observational study was conducted in chronic
hepatitis C patients treated with conventional interferon 3 MIU
thrice weekly and ribavirin 400 mg bid for 24 weeks. All patients
had raised ALT levels for last 06 months, had positive PCR for
HCV RNA by real time method and liver biopsy was done. Platelet
counts along with hemoglobin concentration and TLC were moni-
tored in all patients on monthly basis. Data was analyzed by using
SPSS 13.0
Results: Out of 422 patients 15% (n=63) developed thrombocy-
topenia at 12 weeks whereas out of the remaining 359 patients
another 6% (n=22) developed thrombocytopenia at 24 weeks of
therapy. 70 Patients had platelet count in the range of 100-
150,000 cells/cmm. 11 patients had platelet count less than
100,000 cells/cmm and 02 patients had platelet count less than
50,000 cells/cmm.
Conclusion: We conclude that thrombocytopenia is present in a
signiﬁcant number of patients receiving conventional interferon
and ribavirin therapy (15% at week 12 and 6% at week 24). 02
patients needed discontinuation of therapy.
PP-133 Correlation of alanine aminotransferase (ALT)
levels with necroinﬂammatory score and stage of
ﬁbrosis on liver biopsy in chronic hepatitis C
patients
Adnan Raja*, Muhammad Umar, Hammamatul Bushra.
Gastroenterology and Hepatology division, Department of
Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Background/Aims: Hepatitis C is the most common cause of
Chronic Liver Disease in Pakistan with HCV prevalence of 4%.
Liver Biopsy is done for suitability of treatment based on necroin-
ﬂammatory score (grade) and stage of ﬁbrosis. The aim of this
study is to evaluate the staging and grading of histological
changes on liver biopsy in Chronic Hepatitis C patients and its
correlation with serum ALT levels.
Methods: Retrospective descriptive study on the patient records
at Gastroenterology and Hepatology division of Holy Family Hos-
pital including patients of Chronic Hepatitis C undergoing ﬁrst
liver biopsy with no prior treatment and excluding those with
other indications for biopsy. Data was analyzed using SPSS 13.
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Results: Among 518 liver biopsies, the most frequent histological
ﬁnding was Mild Chronic Hepatitis (57.1%, n=296) followed by
moderate Chronic Hepatitis (41.5%, n=215) and Severe Chronic
Hepatitis was found in 7 patients (1.4%).
87.5% patients had grade 0-8 (mild chronic inﬂammation) accord-
ing to HAI scoring system. 56.6% (n=293) patients had no ﬁbrosis
(stage 0), 42.8% (n=222) had some degree of ﬁbrosis (stage 1-5)
and 0.6% n=3 had cirrhosis (stage 6) on liver biopsy according to
HAI scoring system.
Among those with normal ALT 63% had mild inﬂammation and 37%
had moderate to severe inﬂammation. About 54.5% of those with
high ALT also had mild inﬂammation and 45.5% had moderate to
severe inﬂammation.
Conclusion: Thus there was no statistically signiﬁcant relation-
ship between ALT levels and the severity of Inﬂammation on Liver
Biopsy (p value of 0.085)
PP-134 HCV F protein, a protein correlating with HCV
chronic infection
Jing Kong*, Xiaozhao Deng, Zhongchan Wang, Yun Zhang,
Chunli Chu. Huadong Research Institute for Medicine and
Biotechniques
Objectives: Hepatitis C virus (HCV) produces a novel protein,
known as F protein. F protein is encoded by an open reading
frame (ORF) that overlaps the core gene in the +1 frame (core
+1 ORF). In this study, we attempt to understand the biological
functions of the F protein in the pathogenesis of HCV infection.
Methods: HCV F protein, a +1 frameshifting at codon 42 followed
by a rephasing in the normal open reading frame at stop codon
144, from the genotype 1b are expressed in E. coli. Proteins from
E. coli lysates transformed with pGEX-F and the corresponding
empty vector (pGEX-4T-2) were subjected to 10% SDS-PAGE and
detected using Western blotting. The presence of antibodies
speciﬁc for the novel F protein was evaluated in the serum of
patients with an indirect ELISA.
Results: E. coli BL21 (DE3) cells harboring the plasmids were
harvested, and lyzed in SDS sample buffer and examined for the
production of aimed protein about 43kD on SDS-PAGE.
Results: of indirect ELISA carried out on 120 serum samples
from 28 acute HCV patients, 62 chronic HCV patients, 30 hepatic
cirrhosis, and 10 healthy samples. Sera of 54% (15/28) of the HCV
acute patients reacted with F protein, compared to 37 of the 62
(60%) chronic patients, and 20 of 30 (67%) liver cirrhosis infected
with HCV, and this association reached statistical signiﬁcance.
Conclusion: F protein may intimately linked to the molecular
pathogenesis in HCV-infected individuals.
PP-135 Up-regulation of HCV p7 on ASGPR1 gene
promoter
Jiang Guo*. Institute of Infectious Diseases, Beijing Ditan
Hospital, Beijing, China
Background: To investigate the transregulating effect of HCV p7
on ASGPR1 gene promoter.
Methods: Polymerase chain reaction (PCR) technique was em-
ployed to amplify the coding sequence of ASGPR1 promoter from
HepG2 genomic DNA, and the product was subcloned into pCAT3-
Basic by Kpn I and Bgl II, named pCAT3-ASGPR1p. pCAT3-ASGPR1p
was transfected into the hepatoblastoma cell line HepG2, then
cotransfected with pcDNA3.1(–)-HCV p7 by FuGENE 6 transfec-
tion reagents. The HepG2 cells transfected with pCAT3-Basic was
used as negative control. The activity of CAT in HepG2 cells
transfected was detected by a ELISA kit after 48 hours, which
reﬂected the transregulating function of pcDNA3.1(–)-HCV p7 to
ASGPR1 gene promoter.
Results: The report vector pCAT3-ASGPR1p has been constructed
and had been conﬁrmed by restriction enzyme digestion and
sequencing. The expression of CAT in HepG2 cells co-transfected
with pCAT3-ASGPR1p and pcDNA3.1(–)-HCV p7 was 7.7 times
as higher as that of pCAT3-Basic,and 2.4 as higher as that of
pCAT3-ASGPR1p.
Conclusions: HCV p7 can transregulate ASGPR1 promoter, and so
can up-regulate the expression of ASGPR1 gene.
PP-136 Liver steatosis and treatment of hepatitis C viral
infection
Gulnara Aghayeva*, Ali Hidayatov. Internal Diseases
Department, Azerbaijan State Medical University
Objectives: There has been increasing evidence indicating
metabolic disturbances in HCV infection, which would inﬂuence
to pathogenesis and treatment of chronic hepatitis C.
Methods: We compared results of therapy with pegylated
interferon-alfa plus ribavirin in 79 patients (52%-male) with
HCV. The excessive weight was estimated with body mass index
(BMI). Patients were divided into 3 groups: 1st group with BMI <
25 kg/m2 (27), 2nd group with BMI - 26-30 kg/m 2 (30), 3rd group
with BMI> 30 kg/m2 (22).
Result: After antiviral therapy 59 patients (74,6%) had achieved
sustained virologic response SVR - 68,5% in genotype 1 (37 pa-
tients) and 88% in genotypes 2 and 3 (22). In the third group
(BMI>30 kg/m2) was lowest level of SVR (55,6%). There were high
authentic differences in each group among SVR rate in patients
with and without liver steatosis (p<0.05). Patients without liver
steatosis had SVR in 91% (1st group – 84,2%, 2nd and 3rd groups
– 100%). Patients with steatosis achieved SVR in 45% (1st group
– 37,5%, 2nd group – 70,6% and 3 group – 55,6%). All patients
without liver steatosis in the third group had achieved SVR, on
the other hand just 26.3% patients with steatosis in the same
group had achieved SVR (p<0.05).
Conclusion: The presence of hepatic steatosis is risk factor in
chronic hepatitis C patients. Improvement of the results of an-
tiviral therapy correction concerning liver steatosis is necessary,
both before as well as during the treatment of viral hepatitis
C.
PP-137 The prognostic signiﬁcance of hepatocyte growth
factor activator in liver biopsies of Egyptian
patients with HCV-related chronic hepatitis
Nermine Ehsan1,2, Doha Maher*,1,2, Rehab Samaka2,3,
Hayam Aiad2,3. 1National Liver Institute; 2Menouﬁya University;
3Faculty of Medicine
Background: Hepatocyte growth factor activator (HGFA), is a
pericellular activator of hepatocyte growth factor (HGF) which
plays a potent role in liver repair after injury.
Objectives: The aims of this study were to investigate the im-
munostaining of HGFA in liver tissues from patients with hepatitis
C virus (HCV) infection and to correlate its expression with
the grade of activity, stage of ﬁbrosis and immunohistochemical
expression of transforming growth factor beta1 (TGF-β1).
Methods: Parafﬁn embedded liver sections prepared from 31
biopsies of patients with HCV-related chronic hepatitis (41±8 y)
and 20 normal healthy subjects, donors for liver transplantation
(29±7.5 y) were evaluated for grading and staging of chronic
hepatitis according to Ishak scoring system and applied for im-
munostaining with HGFA and TGF-β1. Semiquantitative analysis
of immunoreactive cells’ intensity and percentage for HGFA and
TGFβ1 were interpreted to calculate the H-score.
Results: Liver tissue from HCV related chronic hepatitis revealed
preferential distribution of HGFA around sites of injury and re-
generation. HGFA H-score correlated signiﬁcantly with the grade
of activity and stage of ﬁbrosis (p<0.01 each) and a highly
statistical signiﬁcant direct correlation between TGF-β1 H-score.
There was a high statistically signiﬁcant difference between nor-
